Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) had its price target decreased by JMP Securities from $25.00 to $21.00 in a research note released on Monday, The Fly reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.
Several other analysts have also commented on IOVA. Guggenheim assumed coverage on shares of Iovance Biotherapeutics in a research report on Monday, October 31st. They issued a neutral rating on the stock. Oppenheimer lowered their price objective on shares of Iovance Biotherapeutics from $27.00 to $25.00 in a research report on Friday, November 18th. Robert W. Baird lowered their price objective on shares of Iovance Biotherapeutics from $34.00 to $25.00 and set an outperform rating on the stock in a research report on Friday, August 5th. Piper Sandler lowered their price objective on shares of Iovance Biotherapeutics from $13.00 to $11.00 and set a neutral rating on the stock in a research report on Sunday, November 20th. Finally, Truist Financial lowered their price objective on shares of Iovance Biotherapeutics to $18.00 in a research report on Tuesday, August 23rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $22.40.
Iovance Biotherapeutics Price Performance
IOVA opened at $6.22 on Monday. The company’s 50-day moving average is $8.93 and its 200 day moving average is $10.50. Iovance Biotherapeutics has a fifty-two week low of $5.42 and a fifty-two week high of $20.60. The firm has a market capitalization of $981.76 million, a P/E ratio of -2.52 and a beta of 0.50.
Hedge Funds Weigh In On Iovance Biotherapeutics
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.